Clorox stock (CLX) ends week higher: what to watch on dividend, Glad shift, ERP fallout

NEW YORK, January 11, 2026, 17:20 EST — Market closed.

Shares of The Clorox Company (NYSE: CLX) rose about 1.9% to $106.19 on Friday, their third straight gain, and beat smaller moves in Procter & Gamble and Colgate-Palmolive as U.S. stocks advanced. Volume was 1.9 million shares, below the stock’s 50-day average, and the close left Clorox about 35% under its 52-week high. (MarketWatch)

Why it matters now: investors are still trying to gauge how quickly Clorox can steady shipments after a U.S. enterprise resource planning, or ERP, transition — software that runs ordering, inventory and billing — that disrupted fulfillment and weighed on market share. The company said retailers built about two weeks of inventory ahead of the cutover and then drew it down, a swing it expects to shave about 90 cents from fiscal 2026 earnings per share. “As with any rollout of this scale, we experienced some temporary disruptions that affected our market share,” CEO Linda Rendle said. (The Clorox Company Investors)

Another date is closing in fast: the Glad bags and wraps joint venture. Clorox and Procter & Gamble said they will wind down the Glad venture as of Jan. 31, 2026, with Clorox intending to buy P&G’s 20% stake at the termination and continue licensing some P&G trademarks such as Febreze and Gain. “We achieved better-than-expected results across sales, margin and EPS in the second quarter,” Rendle said in that announcement. (The Clorox Company Investors)

Cash gets a sharper look in January. A filing showed Clorox said current liabilities exceeded current assets as of Sept. 30 because a Glad venture agreement terminal obligation was coming due for payment in January 2026. (SEC)

Clorox last reported earnings on Nov. 3, when it said revenue fell 19% to $1.43 billion but it beat analysts’ profit expectations, helped by steady demand in its cleaning products. It reiterated its fiscal 2026 outlook for sales down 6% to 10% and adjusted profit of $5.95 to $6.30 per share. (Reuters)

Dividend watchers have their own checkpoint. Clorox said in November its board declared a quarterly dividend of $1.24 per share, payable Feb. 13, 2026, to shareholders of record at the close of business on Jan. 28. (PR Newswire)

With the market shut for the weekend, Monday’s open will test whether Friday’s bid for staples holds up once volume returns. Traders will also be watching whether the stock stays firm into the late-January calendar after a thin run.

But the near-term risk is execution. Any renewed snag in order processing, or another bout of retailer inventory caution, could keep shipments choppy longer than investors expect and delay any margin recovery.

The next marked date is Jan. 28, when Clorox shares are slated to trade ex-dividend — the first session the stock typically trades without the right to that upcoming payout. (Yahoo)

Khadija Saeed Latest posts

A dedicated markets reporter, she covers stocks, macroeconomics, and major business developments with a sharp eye for detail and accuracy.

View all

Appian valuation in flux after results as narrative fair value and DCF diverge
January 11, 2026, 7:00 PM EST. Appian (APPN) posted revenue of US$690.8 million and a net loss of US$7.3 million. The stock's path is mixed: a 1-month decline of 10.65% and a 90-day return of 18.51%, with a 1-year return near flat and a 5-year total shareholder return at a loss of 80.08%. The close at US$33.80 sits below a narrative fair value of US$41.60, implying upside if the earnings path proves durable. Analysts expect revenue growth of about 10.3% annually over the next three years. But Simply Wall St's DCF (discounted cash flow) model assigns a fair value of US$27.17, suggesting the shares are overvalued at current levels. The divergence raises the question: is the narrative too optimistic or is the cash-flow picture too cautious? Risks include competition from larger low-code peers and ongoing investments in R&D and sales.